OmniAb (OABI) Other Non-Current Assets (2021 - 2026)
OmniAb (OABI) reported Other Non-Current Assets of $795000.0 for Q1 2026, down 37.99% year-over-year from $1.3 million in Q1 2025, and up 41.96% on a QoQ basis from $560000.0 in Q4 2025.
OmniAb (OABI) has 6 years of Other Non-Current Assets data on file, last reported at $795000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 37.99% year-over-year to $795000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $795000.0 (down 37.99% YoY) and the FY2025 annual result came in at $560000.0, changed 0.0% from the prior year.
- Other Non-Current Assets improved to $795000.0 in Q1 2026 per OABI's latest filing, from $560000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $3.3 million in Q2 2023 and bottomed at $560000.0 in Q2 2024.
- The 5-year median for Other Non-Current Assets is $1.5 million (2024), against an average of $1.8 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets jumped 109.22%; it then slumped 83.26% in 2024.
- Tracing OABI's Other Non-Current Assets over 5 years: stood at $3.1 million in 2022, then tumbled by 30.19% to $2.2 million in 2023, then slumped by 74.37% to $560000.0 in 2024, then changed by 0.0% to $560000.0 in 2025, then soared by 41.96% to $795000.0 in 2026.
- Per Business Quant, the three latest OABI Other Non-Current Assets figures stand at $795000.0 (Q1 2026), $560000.0 (Q4 2025), and $1.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 795,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 795,000.00 |
| Dec 31, 2025 | 560,000.00 |
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 560,000.00 |
| Sep 30, 2024 | 1.62 Mn |
| Jun 30, 2024 | 560,000.00 |
| Mar 31, 2024 | 1.93 Mn |
| Dec 31, 2023 | 2.19 Mn |
| Sep 30, 2023 | 3.19 Mn |
| Jun 30, 2023 | 3.35 Mn |
| Mar 31, 2023 | 3.34 Mn |
| Dec 31, 2022 | 3.13 Mn |
| Dec 31, 2021 | 1.50 Mn |
| Jun 30, 2021 | 597,270.00 |